Lenzilumab treatment for rare blood cancers are expanding 2023.

A cutting-edge clinical trial for people with a rare blood cancer is being expanded across Australia and potentially beyond.

The study is currently underway at  the Royal Adelaide Hospital and the Austin Hospital in Melbourne. Additional sites to be established in New South Wales, Queensland, Victoria, Tasmania.

Associate Professor Dan Thomas, the head of the Blood Cancer Program with SAHMRI and the University of Adelaide, says more effective treatments for chronic myelomonocytic leukemia (CMML) are desperately needed. The following article is obtained from Sahmri at 14th September 2022 :

Is this pill the gamechanger for rare cancers ?

“The prognosis for people with CMML is poor, with an average survival of around 30 months,” he said.

“Those survival rates have remained essentially unchanged over the past three decades, but in recent years, with the development of lenzilumab, we have cause to be optimistic about better patient outcomes.

“Although clinical trials have been slowed due to COVID staff shortages, doctors are really keen to support the study, including hospitals in New Zealand because there are virtually no treatment alternatives for this disease.”

Lenzilumab has been developed by the US-based biopharmaceutical company Humanigen, which is supplying the treatment for this study. The trial is being sponsored by SAHMRI and supported by a grant from the Medical Research Future Fund.

Humanigen Chairman and CEO Cameron Durrant says expanding the number of study sites could enable more people who are diagnosed with this rare cancer to participate.

“Lenzilumab was discovered in Australia, so it is only fitting that we leverage the wealth of local knowledge that exists for lenzilumab as we continue clinical development,” he said.

“Associate Professor Thomas is a world expert in CMML and SAHMRI is a leader in precision medicine that assists patients in finding the proper treatment for their cancer.”

The Precision Approach to Chronic Myelomonocytic Leukemia (PREACH-M) trial is open to newly diagnosed CMML patients who haven’t had any treatment yet but are beginning to have symptoms including low blood counts, high fevers, enlarged spleens or high white cell counts and who generally feel unwell. Until now, these patients have been limited to having blood transfusions and supportive care.

Anyone who is interested in learning more about the study, or additional information can visit the Australian New Zealand Clinical Trials Registry. Investigators expect to see preliminary results from the study in the first half of 2023.

The incidence of CMML in the US, UK, and Australia is about 1,700 patients annually. As it is a rare disease, lenzilumab might qualify for certain regulatory and commercial advantages that could accelerate development and approval. Humanigen and the Principal Investigator are assessing regulatory pathways that may enable early results to support a regulatory submission and potential approval by the Therapeutic Goods Administration in Australia, which could be expanded through Project Orbis to the United States and the United Kingdom. End of article.

The owner of this website also have an financial interest in Humanigen as a shareholder. This is not financial or medical advice. The share price of this company went from around 25 dollars at the beginning of 2021 to 15 cents as of September 2022. One of the biggest falls of any company listed on the Nasdaq. Biotech investments are one of the riskiest, but also most rewarding opportunities if they can make it work.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: